Russian BIOCAD corporation has come up with an innovative drug against breast cancer.

      The medication is under preclinical studies. It is intended to be introduced in the market in 2020.

      The amoung of over one million dollars has been invested in the project. The developers claim that the medicine will work both at the early and late stages of the disease.

      According to Mr. Roman Ivanov, the vice-president for development and research of the BIOCAD company, the medication is of unique structure.

      "Monoclonal anti-HER2 antibody is added fragments of other antibody, which is specific to the receptor HER3. Thus, the preparation is empowered with double specificity that considerably increases its efficiency and makes it possible to expand the area of its application" — Mr. Ivanov explained.